NEW YORK, May 24, 2026, 13:02 (EDT)
ProQR Therapeutics N.V. stock was volatile going into the Memorial Day break, with shares trading on Nasdaq getting a bump Friday before fading a bit after hours. PRQR ended the regular session May 22 at $1.56, up 8.3%, then edged down to $1.54 after the close.
No trading Monday, so ProQR’s clinical update won’t get a price check until Tuesday. Nasdaq has U.S. equity markets closed May 25 for Memorial Day. The next regular session is Tuesday, when traders get to act.
ProQR shares ended the week off about 1.9%, settling at $1.59 on May 15. The stock dropped early in the week before bouncing late. The SPDR S&P Biotech ETF, which tracks smaller biotech names, was up around 0.7% in the same period. ProQR trailed the ETF even with its move on Friday.
AX-0810, the main RNA-editing drug from ProQR, is the company’s focus now. RNA editing looks to change RNA—the messenger for making proteins—instead of altering DNA. ProQR said it still expects to deliver AX-0810 target-engagement data in the second quarter, showing if the drug is hitting the right biological target.
ProQR CEO Daniel A. de Boer said the company “on track to deliver multiple clinical readouts” is putting the focus on biliary atresia for the next step with AX-0810. Biliary atresia is a liver disease involving bile flow. The company has said both AX-0810 and its next program, AX-0811, aim to cut bile-acid reuptake in the liver. ProQR Therapeutics
ProQR’s Q1 update left investors waiting for more. The company finished March with €81.1 million in cash and equivalents, saying that should cover operations into mid-2027. Net loss for the quarter grew to €13.4 million from €10.1 million a year ago.
ProQR’s annual general meeting is coming up June 2 in Amsterdam. The company told shareholders meeting documents have been posted on its investor page and with the SEC.
Mixed signals from competitors. Wave Life Sciences last week gave updated WVE-006 results in alpha-1 antitrypsin deficiency and said it’s waiting for FDA feedback on a possible accelerated approval path by mid-2026. University of Chicago’s D. Kyle Hogarth called the Wave results “a major step forward,” setting another bar for what clinical validation looks like in RNA editing. Wave Life Sciences
Korro Bio, a smaller name in RNA editing, has been setting up conference talks on its OPERA platform and liver-disease program, with a poster at the EASL Congress scheduled for May 27-30. On Friday, shares of Wave dipped 0.7%, while Korro added 3.7%. The moves show the RNA-editing trade is still thin and driven by single stocks.
But there are tradeoffs. AX-0810 is in early stages, and healthy-volunteer target-engagement results might not answer if patients will see benefit, how long a dose lasts, or if it’s safe. ProQR also noted it faces risks with clinical timelines, regulatory reviews, running trials in China, and that later data could differ from these first results.
PRQR’s jump Friday is mostly about positioning, not conviction. After a week cut short by the holiday, traders will watch what happens when Nasdaq opens. They’ll have to decide if the stock above $1.50 means biotech buyers are betting on clinical data, or if this is just a thin-name pop ahead of the long weekend.
